FDG PET/CT in Pancreatic and Hepatobiliary Carcinomas: Value to Patient Management and Patient Outcomes.

Journal Article (Journal Article;Review)

Fludeoxyglucose F 18 ((18)F-FDG) PET/CT has not been shown to offer additional benefit in the initial diagnosis of pancreatic cancer, but studies show benefit of (18)F-FDG PET/CT in initial staging and patient prognosis. There is evidence for (18)F-FDG PET and (18)F-FDG PET/CT in staging and prognosis of cholangiocarcinoma and gallbladder cancer. (18)F-FDG PET/CT has shown promise in staging liver malignancies by detecting extrahepatic metastasis. There is evidence supporting the ability of PET/CT in predicting prognosis in patients with hepatocellular carcinoma. Evidence is evolving for the role of (18)F-FDGPET/CT in predicting prognosis and survival in patients with colorectal liver metastasis.

Full Text

Duke Authors

Cited Authors

  • Parikh, U; Marcus, C; Sarangi, R; Taghipour, M; Subramaniam, RM

Published Date

  • July 2015

Published In

Volume / Issue

  • 10 / 3

Start / End Page

  • 327 - 343

PubMed ID

  • 26099670

Electronic International Standard Serial Number (EISSN)

  • 1879-9809

Digital Object Identifier (DOI)

  • 10.1016/j.cpet.2015.03.001


  • eng

Conference Location

  • United States